A phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of jcar017 in adult subjects with aggressive b-cell non-hodgkin lymphoma

Study title: 
A phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of jcar017 in adult subjects with aggressive b-cell non-hodgkin lymphoma
Date receipt dossier: 
24 apr 2018
EudraCT number: 
2017-000106-38
Company / Sponsor: 
Celgene
Phase: 
II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
B-cell non-hodgkin lymphoma
Therapeutic approach: 
Immunotherapy
Genetic modification: 
EGFRt en chimeric antigen receptor against CD19
Method of transfer of nucleic acid of interest: 
Lentiviral vector
Administered biological material: 
Autologous Tcells transduced with lentiviral vectors (JCAR017)
Route of administration: 
Intravenous
Locations in Belgium: 
UZ Gent
Type of procedure: 
Contained use only
Current status: 
Assessed